4.0
Aug 3, 2018
Anonymous employee
Current employee, more than 3 years
Recommend
CEO approval
Business Outlook
Pros
Small-company growth opportunities with a larger-company portfolio of mature products. Likely to dominate their market within five years. Part of CSL Limited, perhaps the greatest unsung biopharma story on the planet.
Cons
Procedures and functions are still maturing. Creeping risk of becoming a stodgy bureaucracy. Long-term incentive plans not competitive in some markets.